^
Association details:
| Biomarker: | MYB-NFIB fusion + BCOR F1106Tfs*5 + BCOR L1524Hfs*8 |
|---|---|
| Cancer: | Adenoid Cystic Carcinoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
Published date:
07/26/2021
Excerpt:
...we report a case of rare perianal ACC who received resection and palliative adjuvant radiation….Further next-generation sequencing analysis of perianal tissue demonstrated the v-myb avian myelobastosis viral oncogene homolog and nuclear factor I/B fusion gene and two novel BCL-6 corepressor (BCOR) mutations (p.F1106Tfs*5 and p.L1524Hfs*8). The therapy was switched to eribulin and anlotinib and has been performed for eight cycles....This study presented the first case of perianal ACC with multiple pulmonary metastases and particular BCOR mutations, who presented a durable response to eribulin and anlotinib, providing a potential therapeutic option for advanced refractory ACC.
DOI:
10.1097/CAD.0000000000001171
